Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04599504

Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)

This study will test the effectiveness of lisdexamfetamine medication as a treatment for loss-of-control eating and weight following bariatric surgery. This is a controlled test of whether, amongst non-responders to acute treatments, lisdexamfetamine medication results in superior outcomes compared with placebo.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Yale School of Medicine

New Haven, Connecticut, 06519, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be in the age range ≥18 years of age and <65 years of age.
  • Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy
  • Approximately ten months post-surgery
  • Experienced regular loss of control eating about six months after bariatric surgery, and were considered treatment non-responders to a four-month treatment trial of medication and/or BWL
  • Be an otherwise healthy subject without uncontrolled medical problems, as determined by the study physician and medical co-investigators (physical examination, laboratory studies).
  • Read, comprehend, and write English at a sufficient level to complete study-related materials.
  • Provide a signed and dated written informed consent prior to study participation.
  • Be available for participation in the study for up to 15 months (3-month treatment plus 12-month follow up).

Exclusion criteria

  • Has a predisposition to seizures (e.g., subject with a history or evidence of seizure disorder, febrile seizures during childhood, brain tumor, cerebrovascular disease, or significant head trauma; has a family history of idiopathic seizure disorder or is currently being treated with medications or treatment regimens that lower seizure threshold).
  • Has a history of anorexia nervosa or history of bulimia nervosa.
  • Is currently using other medications for weight loss.
  • Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression)
  • Has untreated hypertension with a seated systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg, or heart rate > 100 beats/minute.
  • Has a history of congenital heart disease, cardiovascular disease, cardiac arrhythmias requiring medication, or a history of cerebrovascular pathology including stroke.
  • Has current uncontrolled hypertension.
  • Has current uncontrolled Type I or Type II diabetes mellitus.
  • Has untreated hypothyroidism with a TSH > 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit.
  • Has gallbladder disease.
  • Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder.
  • Is currently in active treatment for eating or weight loss.
  • Is currently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device.
  • Is breast-feeding or is pregnant or is not using a reliable form of birth control.
  • Reports active suicidal or homicidal ideation.
  • Previous history of problems with LDX or other stimulants.
  • Has a history of allergy or sensitivity to LDX or other stimulant medications.
  • Current medication contraindicated with study medication.
  • Any current psychostimulant use or any medication for ADHD.
  • History or current alcohol or substance use disorder (smoking will not be exclusionary)
  • Is currently taking MAOI medication, SSRI medication, or strong inhibitors of CYP2D6

Treatment and study plan

Lisdexamfetamine Dimesylate (Medication)

Drug

Medication will be taken daily in pill form.

Other names: Vyvanse

Placebo

Other

Placebo will be inactive and taken daily in pill form.

Primary outcomes

  1. Loss-of-Control Eating Frequency

    Time frame: From baseline interview at study enrollment to after the 12-week treatment

    Loss-of-control eating frequency is a continuous variable of loss-of-control eating episodes assessed using the Eating Disorder Examination interview; Loss-of-control eating frequency will be based on the past 28 days and defined as loss-of-control eating episodes per month.

  2. Loss-of-Control Eating Frequency

    Time frame: From post-treatment to the 6-month follow-up

    Loss-of-control eating frequency is a continuous variable of loss-of-control eating episodes assessed using the Eating Disorder Examination interview; Loss-of-control eating frequency will be based on the past 28 days and defined as loss-of-control eating episodes per month.

  3. Loss-of-Control Eating Frequency

    Time frame: From post-treatment to the 12-month follow-up

    Loss-of-control eating frequency is a continuous variable of loss-of-control eating episodes assessed using the Eating Disorder Examination interview; Loss-of-control eating frequency will be based on the past 28 days and defined as loss-of-control eating episodes per month.

  4. Body Mass Index (BMI)

    Time frame: From baseline at study enrollment to after the 12-week treatment

    BMI is calculated using measured height and weight

  5. Body Mass Index (BMI)

    Time frame: From post-treatment to the 6-month follow-up

    BMI is calculated using measured height and weight

  6. Body Mass Index (BMI)

    Time frame: From post-treatment to the 12-month follow-up

    BMI is calculated using measured height and weight

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registry information

Official study title

Pharmacological and Behavioral Treatments to Treat Loss-of-Control Eating and Improve Weight Outcomes After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Oct 22, 2020
Registry last updated
Feb 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.